Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Clinical implications of using molecular diagnostics for ovarian cancers.
Annals of oncology : official journal of the European Society for Medical Oncology·2013
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology·2013
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
British journal of cancer·2013